57 related articles for article (PubMed ID: 21676483)
1. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Ren S; Zhou S; Wu F; Zhang L; Li X; Zhang J; Xu J; Lv M; Zhang J; Zhou C
Lung Cancer; 2012 Jan; 75(1):102-9. PubMed ID: 21676483
[TBL] [Abstract][Full Text] [Related]
2. Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.
Jiang T; Li X; Wang J; Su C; Han W; Zhao C; Wu F; Gao G; Li W; Chen X; Li J; Zhou F; Zhao J; Cai W; Zhang H; Du B; Zhang J; Ren S; Zhou C; Yu H; Hirsch FR
Theranostics; 2017; 7(19):4753-4762. PubMed ID: 29187901
[No Abstract] [Full Text] [Related]
3. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.
Wang SS; Zimmermann M; Zhang H; Lin TY; Malfatti M; Haack K; Turteltaub KW; Cimino GD; de Vere White R; Pan CX; Henderson PT
Int J Cancer; 2017 Aug; 141(3):604-613. PubMed ID: 28437852
[TBL] [Abstract][Full Text] [Related]
4. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Sito H; Tan SC
Mol Biol Rep; 2024 Jan; 51(1):102. PubMed ID: 38217759
[TBL] [Abstract][Full Text] [Related]
6. Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration-induced nephropathy.
Mitarai Y; Tanino R; Nakashima K; Hotta T; Isobe T; Tsubata Y
Br J Clin Pharmacol; 2023 Dec; 89(12):3551-3560. PubMed ID: 37452621
[TBL] [Abstract][Full Text] [Related]
7. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract][Full Text] [Related]
9. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.
Dong J; Hu Z; Shu Y; Pan S; Chen W; Wang Y; Hu L; Jiang Y; Dai J; Ma H; Jin G; Shen H
Mol Carcinog; 2012 Jul; 51(7):546-52. PubMed ID: 21739480
[TBL] [Abstract][Full Text] [Related]
10. The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer.
Jiang C; Guo Y; Li Y; Kang J; Sun X; Wu H; Feng J; Xu Y
J Thorac Dis; 2021 May; 13(5):3126-3136. PubMed ID: 34164203
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer.
Casal-Mouriño A; Ruano-Ravina A; Torres-Durán M; Parente-Lamelas I; Provencio-Pulla M; Castro-Añón O; Vidal-García I; Abal-Arca J; Piñeiro-Lamas M; Fernández-Villar A; Valdés-Cuadrado L; Barros-Dios JM; Pérez-Ríos M
Sci Rep; 2020 Dec; 10(1):21147. PubMed ID: 33273562
[TBL] [Abstract][Full Text] [Related]
12. Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy.
Wang C; Yang D; Zhang X; Zhang X; Yang L; Wang P; Zhou W; Li H; Li Y; Nie H; Li Y
Front Genet; 2020; 11():298. PubMed ID: 32391045
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.
Rao D; Mallick AB; Augustine T; Daroqui C; Jiffry J; Merla A; Chaudhary I; Seetharam R; Sood A; Gajavelli S; Aparo S; Rajdev L; Kaubisch A; Chuy J; Negassa A; Mariadason JM; Maitra R; Goel S
Oncotarget; 2019 Sep; 10(53):5510-5522. PubMed ID: 31565185
[TBL] [Abstract][Full Text] [Related]
14. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
Tan LM; Qiu CF; Zhu T; Jin YX; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jul; 7(1):5593. PubMed ID: 28717179
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer in women.
Barrera-Rodriguez R; Morales-Fuentes J
Lung Cancer (Auckl); 2012; 3():79-89. PubMed ID: 28210127
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.
Zienolddiny S; Skaug V
Lung Cancer (Auckl); 2012; 3():1-14. PubMed ID: 28210120
[TBL] [Abstract][Full Text] [Related]
17. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.
Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H
Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648
[TBL] [Abstract][Full Text] [Related]
18. A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.
Han Y; Liu J; Sun M; Zhang Z; Liu C; Sun Y
Dis Markers; 2016; 2016():7643981. PubMed ID: 27057082
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.
Dumont A; Pannier D; Ducoulombier A; Tresch E; Chen J; Kramar A; Révillion F; Peyrat JP; Bonneterre J
Springerplus; 2015; 4():327. PubMed ID: 26180747
[TBL] [Abstract][Full Text] [Related]
20. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
Roco A; Cayún J; Contreras S; Stojanova J; Quiñones L
Front Genet; 2014; 5():391. PubMed ID: 25452763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
